The fight between the Federal Trade Commission (FTC) and Teva Pharmaceutical over the drug maker’s Orange Book patent listings on inhaler products have reached a new level with FTC now going to court to back a press by Teva’s rival generic drug maker to get Teva to remove its patents from the Orange Book. Senate health committee Chair Bernie Sanders (I-VT) says there are indications Teva plans to lower its inhaler prices, but legal experts say that would sidestep the...